IC14 Antibodies to Treat Individuals With Acute Lung Injury
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II, randomized, double-blind, placebo-controlled, safety and efficacy study
of a recombinant chimeric monoclonal antibody against CD14 (IC14) in hospitalized patients
with acute lung injury (ALI).
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI) University of Washington